COPD in patients with stable heart failure in the primary care setting

Mark J Valk1
Berna D Broekhuizen1
Arend Mosterd1,2
Nicolaas P Zuithoff1
Arno W Hoes1
Frans H Rutten1

1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 2Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands

Introduction

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common in the elderly, and often coexist.1 Diagnosing COPD in HF is challenging because clinical features overlap, and dyspnea and fatigue are common symptoms.1,2 Both share smoking as an important risk factor, and they have a chronic progressive disease trajectory with systemic effects, and require complex treatment regimens.3–5 The prognosis of patients with both disorders is worse than those with only one of the diseases.6,7 Importantly, bronchodilators may improve symptoms of COPD, but possibly cause cardiac side effects.8,9 Under-diagnosis of one disease in the presence of another is an important issue,10,11 but also there is a risk of over-diagnosing COPD in patients with HF if these patients are not stable and have some pulmonary congestion.12 Pulmonary congestion is common in those hospitalized for an exacerbation of HF, and this may mimic COPD clinically, but also spirometrically. Spirometry at discharge in that situation would show – caused by pulmonary congestion – a larger reduction in forced expiratory volume in 1 second (FEV1) than in forced vital capacity (FVC), resulting in a risk of over-diagnosing COPD.13,14 When patients with HF are stable and euvolemic, the FEV1...
FVC allows to adequately detect COPD, although, both the FEV₁ and the FVC are reduced to a similar extent. Diagnosing COPD at the right moment is therefore key in patients with HF.

Earlier reports on the prevalence of co-morbid COPD in HF often relied on previous documentation of COPD, or on spirometry results performed in HF patients when unstable. Prevalence estimates ranged from 9% to 52%. Data in a representative sample of patients with HF in a stable phase of their disease, also including patients with preserved ejection fraction (PEF), are still lacking.

The aim of our study was to provide a valid prevalence estimate of COPD in a representative sample of patients with HF while in a stable condition (ClinicalTrials.gov identifier NCT01662323).

Methods
Design and study population
In a cross-sectional study we enrolled patients from 30 general practices from the vicinity of Amersfoort, the Netherlands. The study and recruitment period was from November 2010 until October 2011. In total 70,000 persons were enlisted in these practices. In the Netherlands all citizens are registered with a general practitioner (GP), irrespective of cooperative care by a hospital specialist, including those living in a home for the elderly, but excluding those living in a nursing home or hospice. Patients were eligible if they had a diagnosis of HF confirmed by an expert panel consisting of two cardiologists and a GP specializing in HF using all diagnostic information, including echocardiography. The panel based the diagnosis of HF on the criteria of the European Society of Cardiology, that is, suggestive symptoms and objective evidence of cardiac structural or functional cardiac abnormality related to ventricular dysfunction at rest detectable with echocardiography. For HF with reduced ejection fraction (HF-REF) the left ventricular ejection fraction should be <45%. For HF with preserved ejection fraction (HF-PEF) the left ventricular ejection fraction should be ≥45%, in addition to diastolic dysfunction identified by echocardiography. Disagreement between panel members was resolved by majority. We invited 236 patients with a confirmed diagnosis of HF for spirometry, and 121 (51.2%) consented to participate (Figure 1).

The study was approved by the Regional Medical Ethics Committee of the Meander Medical Center, Amersfoort, the Netherlands. All participants gave written informed consent.

Measurements
Between November 2010 and June 2011 baseline characteristics of the participants were extracted from the medical files of the participating GPs. Participants underwent spirometry in the primary care setting performed by trained personnel. Spirometry was performed with SPIDA software (Spida 5) and microloop. Before and after 400 micrograms of salbutamol, the FVC and FEV₁ were measured. COPD was considered present if the post-bronchodilator FEV₁/FVC ratio was below 0.7, as defined by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria. Severity of pulmonary obstruction was expressed as the proportion of the predicted FEV₁ (the latter based on “normal” values as derived from the population at large with the same age, sex, and height) and derived from the forced spirometry. The FEV₁ as percentage predicted was subdivided into four categories: ≥80, 50–79, 30–49, <30. The quality of the flow-volume curves was assessed by an experienced physician.

Data analysis
We compared HF patients who decided to participate with nonparticipants. In the participants we compared those with and without COPD. In those with COPD, we compared “already known” with “newly detected”. Finally, we compared patients with HF-REF and HF-PEF. Differences between groups were assessed with the chi-square or Fisher’s exact tests for categorical variables, and independent student’s t-test for continuous variables. The prevalence of COPD was calculated with the binominal 95% confidence intervals (95% CIs). All data were analyzed with SPSS version 20.0.

Figure 1 Flow diagram.
Abbreviation: HF, heart failure.
Results
Two-hundred and thirty-six patients with established HF were invited for spirometry. Baseline characteristics of the participants (n=121) were not significantly different from the nonparticipants (n=115) (Table S1). In 15 patients spirometry results were of insufficient quality, leaving 106 for this analysis (Figure 1). The mean age of the 106 participants was 76.0 (standard deviation [SD] 11.9) years, and 57% were male. The prevalence of COPD was 28.3% (95% CI 19.7%–36.9%), with similar rates for those with a REF (28.6% [95% CI 20.0%–37.2%]) and PEF (27.9% [95% CI 19.4%–36.4%]).

Table 1 shows patient characteristics of all 106 patients. On average, patients with COPD were older than those without COPD. Mean FEV₁% predicted was 65.8 (SD 19.5) and 73.9 (SD 10.9) for those with newly detected COPD and without COPD, respectively. Seventy percent of the subjects with COPD was previously undiagnosed by their GP. None of the patients with COPD had a history of asthma. Table 2 shows the patient characteristics of newly detected cases vs HF patients without COPD. In Table 3 we compared patients with HF-REF and HF-PEF. The mean post-dilator FEV₁ % predicted was approximately 80% for both HF-REF and HF-PEF patients. Patients with HF-REF were more often male than those with HF-PEF.

Discussion
In our study among stable community-dwelling HF patients the prevalence of COPD was 28.3%, and in 70% this was a new diagnosis of COPD. Prevalence rates were comparable for the subgroups of HF-REF and HF-PEF.

| Characteristics                        | Total (n=106) | Newly detected COPD (n=21) | Known COPD (n=9) | No COPD (n=76) |
|----------------------------------------|---------------|---------------------------|------------------|---------------|
| Mean age in years (SD)                 | 76.0 (11.9)   | 76.9 (11.7)               | 76.4 (10.9)      | 75.8 (12.2)   |
| Male sex                               | 60 (56.6)     | 14 (66.7)                 | 9 (100.0)        | 37 (48.7)     |
| HF-REF                                 | 63 (59.4)     | 12 (57.1)                 | 6 (66.7)         | 45 (59.2)     |
| HF-PEF                                 | 43 (40.6)     | 9 (42.9)                  | 3 (33.3)         | 31 (40.8)     |
| Mean FVC as % predicted (SD)           | 86.4 (2.1)    | 83.5 (16.8)               | 95.6 (14.5)      | 86.3 (24.0)   |
| Mean FEV₁ as % predicted (SD)          | 79.6 (21.1)   | 65.8 (19.5)               | 73.9 (10.9)      | 88.9 (22.8)   |
| Mean FEV₁/FVC (SD)                     | 74.5 (11.8)   | 60.2 (9.8)                | 58.0 (5.7)       | 78.3 (14.3)   |
| Smoking*                               |               |                           |                  |               |
| Current                                | 43 (47.3)     | 8 (47.1)                  | 1 (14.3)         | 34 (50.8)     |
| Former                                 | 37 (40.7)     | 9 (52.9)                  | 5 (71.4)         | 23 (34.3)     |
| Never                                  | 11 (12.0)     | 0 (0.0)                   | 1 (14.3)         | 10 (14.9)     |
| Co-morbidities                         |               |                           |                  |               |
| Hypertension                           | 55 (51.9)     | 12 (57.1)                 | 4 (44.4)         | 39 (51.3)     |
| Diabetes mellitus                      | 28 (26.4)     | 2 (9.5)                   | 2 (22.2)         | 24 (31.6)     |
| Prior myocardial infarction            | 35 (33.0)     | 9 (42.9)                  | 4 (44.4)         | 22 (28.9)     |
| Cardiovascular medication              |               |                           |                  |               |
| Diuretics                              | 75 (70.8)     | 13 (61.9)                 | 5 (55.6)         | 57 (75.0)     |
| ACE-i or ARB                           | 67 (63.2)     | 15 (71.4)                 | 4 (44.4)         | 49 (63.6)     |
| β-blockers                             | 55 (51.9)     | 11 (52.4)                 | 6 (66.7)         | 38 (50.0)     |
| Mineralocorticoid receptor antagonists | 35 (33.0)     | 2 (9.5)                   | 1 (11.1)         | 32 (42.1)     |
| Pulmonary medication                   |               |                           |                  |               |
| Inhaled beta-mimetics                  |               |                           |                  |               |
| Short-acting                           | 9 (8.4)       | 4 (19.0)                  | 1 (11.1)         | 4 (5.3)       |
| Long-acting                            | 13 (12.1)     | 3 (14.3)                  | 4 (44.4)         | 6 (7.9)       |
| Inhaled anticholinergics               |               |                           |                  |               |
| Short-acting                           | 10 (9.3)      | 1 (4.8)                   | 2 (22.2)         | 7 (9.2)       |
| Long-acting                            | 3 (2.8)       | 0 (0.0)                   | 3 (33.3)         | 0 (0.0)       |
| Corticosteroids                        |               |                           |                  |               |
| Oral                                   | 3 (2.8)       | 1 (4.8)                   | 2 (22.2)         | 0 (0.0)       |
| Inhaled                                | 14 (13.1)     | 4 (19.0)                  | 4 (44.4)         | 6 (7.9)       |

Notes: Numbers are cases (%) unless mentioned otherwise. *Data on smoking were missing in 15 patients.

Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Our results are in line with previous studies reporting prevalence rates of 9%–52% in patients with HF.2 These previous studies were performed in hospitalized patients with an over-representation of HF-REF, and spirometry was performed while these patients were recently pulmonary fluid overloaded. We could therefore provide a more valid point estimate of the COPD prevalence of the HF population at large than previous studies. A recent study among 118 elderly patients with stable HF and a smoking history of ≥10 pack years also showed a prevalence rate of 30% of COPD, similar to our study, and also a similarly high number of newly detected cases of COPD (64%).20 In this study COPD was also defined according to the GOLD criteria. Moreover, patients were investigated while stable, approximately 3 months after being hospitalized for HF. Separate prevalence rates for HF-REF and HF-PEF, however, were lacking.20

The prevalence of COPD in patients with HF in our study is approximately 1.5 times higher than the expected estimate of 20% in elderly from the population at large.21 We found that the post-bronchodilator FEV₁ in patients with HF was on average 80% of predicted in patients with the same age and length. This is in line with a previous study showing that HF in the absence of COPD may cause a reduction in FEV₁ of approximately 20%, caused by HF itself.15 Thus, classifying severity of COPD based on FEV₁ % predicted may overestimate the severity of obstruction in patients with HF. Because both FVC and FVC as % predicted are reduced approximately 20%, the ratio FEV₁/FVC is not affected.15

### Table 2 Characteristics of the patients with heart failure and a new diagnosis of COPD vs those without COPD

| Characteristics | Newly diagnosed COPD (n=21) | No COPD (n=76) | P-value |
|-----------------|----------------------------|---------------|---------|
| Mean age        | 76.9 (11.7)                | 75.8 (12.2)   | 0.71    |
| Male sex        | 14 (66.7)                  | 37 (48.7)     | 0.14    |
| HF-REF          | 12 (57.1)                  | 45 (59.2)     | 0.87    |
| HF-PEF          | 9 (42.9)                   | 31 (40.8)     | 0.87    |
| Smoking         |                            |               |         |
| Current         | 8 (47.1)                   | 34 (45.8)     | 0.59    |
| Former          | 9 (52.9)                   | 23 (34.3)     | 0.28    |
| Never           | 0 (0)                      | 10 (14.9)     | 0.79    |
| Cardiovascular medication |                |               |         |
| Diuretics      | 13 (61.9)                  | 57 (75.0)     | 0.24    |
| ACE-i or ARB   | 15 (71.4)                  | 48 (63.2)     | 0.48    |
| β-blockers     | 11 (52.4)                  | 38 (50.0)     | 0.85    |
| Mineralocorticoid receptor antagonist | 2 (9.5) | 32 (42.1) | 0.006   |

**Notes:** Numbers are cases (%) unless specified otherwise. Data on smoking were missing in 13 patients.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

A strength of our study is the inclusion of a representative sample of patients with HF in a stable phase of their disease, and we could present prevalence rates for patients with HF-REF and HF-PEF separately.

A limitation is the relatively small sample size and the lack of body box measurements. Measurements of the total lung capacity and the residual volume would have been helpful to refine the diagnosis of COPD, especially in cases with spirometry results around the critical cut-off point of FEV₁/FVC 0.7.22 Importantly, however, previous studies reporting on the prevalence of COPD in HF did not apply pulmonary function tests other than spirometry. Recently, some authors advocated age- and sex-related thresholds for the FEV₁/FVC lower limit of normal to define COPD.19 We did not use one of the suggested lower limit of normal methods, because application in our study would reduce the possibility to compare our results with previous studies. Finally, some COPD cases may in fact represent persistent asthma, or “mixed cases”, however, none of the COPD cases in earlier years had been labeled with asthma by the GP. We therefore preferred to use the GOLD-definition for COPD (a FEV₁/FVC <0.7). Knowledge of co-morbid COPD in patients with HF has clinical implications because for the management of breathlessness there is room for pulmonary inhalation drugs. We have, however, realized that some

### Table 3 Characteristics and spirometry results of the 106 patients with established HF, divided in those with HF-REF and HF-PEF

| Characteristics     | HF-REF (n=63) | HF-PEF (n=43) | P-value |
|---------------------|--------------|--------------|---------|
| Mean age in years   | 73.1 (13.0)  | 80.4 (8.4)   | 0.001   |
| Male sex            | 38 (60.3)    | 22 (51.2)    | 0.35    |
| Confirmed COPD      | 18 (28.6)    | 12 (27.9)    | 0.94    |
| Spirometry results  |              |              |         |
| Mean FVC as % predicted | 85.9 (SD 22.9) | 87.3 (SD 21.4) | 0.77 |
| Mean FEV₁ as % predicted | 79.2 (SD 21.4) | 80.3 (SD 23.7) | 0.82 |
| FEV₁, as % predicted |              |              |         |
| ≥80                 | 7 (11.1)     | 3 (7.0)      | 0.48    |
| 50–79               | 9 (14.3)     | 7 (16.3)     | 0.78    |
| 30–49               | 2 (3.2)      | 2 (4.7)      | 0.70    |
| <30                 | 0 (0)        | 0 (0)        | 1.0     |
| Cardiovascular medication |        |              |         |
| Diuretics          | 41 (65.1)    | 34 (79.1)    | 0.12    |
| ACE-i or ARB       | 45 (71.4)    | 22 (51.2)    | 0.03    |
| β-blockers         | 35 (55.6)    | 20 (46.5)    | 0.36    |
| Mineralocorticoid receptor antagonist | 20 (31.7) | 15 (34.9) | 0.73    |

**Note:** Numbers are cases (%) unless specified otherwise.

**Abbreviations:** HF, heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation; HF-REF, heart failure with reduced ejection fraction; HF-PEF, heart failure with preserved ejection fraction; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
authors suggest that both beta-mimetics and anti-muscarinic agents may harm the heart. HF drugs may be prescribed in patients with COPD, including cardio selective β-blockers. It is, however, important to uptitrare slowly.\textsuperscript{23}

**Conclusion**

COPD is common in patients with HF, both HF-REF and HF-PEF, and remains undetected in the majority of patients. Selective screening of patients with HF when in a stable phase of their disease should be considered.

**Acknowledgments**

We wish to thank the participating patients and GPs, and Sjaane Hilligeheken, Sanne Rooymans, and Sanne Hillebrand for performing the pulmonary function tests. The study was conducted with an unrestricted research grant from the health insurance company Agis Achmea.

**Author contributions**

FHR conceived the study idea. AWH, FHR, AM, and MJV designed the study. MJV did the data acquisition, and MJV, BDB, and NPZ did the statistical analysis. MJV, and BDB drafted the manuscript and all authors contributed to the revision of the manuscript. FHR supervised the study and is guarantor of the study.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? *Eur J Heart Fail.* 2006;8(7):706–711.

2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail.* 2009;11(2):130–139.

3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohn M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2012;33(14):1787–1847.

4. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. *J Am Coll Cardiol.* 2007;49(2):171–180.

5. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med.* 2013;187(4):347–365.

6. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. *Eur J Heart Fail.* 2010;12(7):685–691.

7. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. *Eur J Heart Fail.* 2009;11(12):1182–1188.

8. An DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. *Chest.* 2003;123(6):1964–1969.

9. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. *Drugs Aging.* 2004;21(6):405–414.

10. Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. *J Intern Med.* 2008;264(4):361–369.

11. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. *Eur Heart J.* 2005;26(18):1887–1894.

12. Brenner S, Guder G, Berliner D, et al. Airway obstruction in systolic heart failure – COPD or congestion? *Int J Cardiol.* 2013;168(3):1910–1916.

13. Dimopoulou I, Daganou M, Tzintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. *Respir Med.* 1998;92(12):1321–1325.

14. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. *Int J Cardiol.* 1987;17(2):207–209.

15. Guder G, Rutten FH, Brenner S, et al. The impact of heart failure on the classification of COPD severity. *J Card Fail.* 2012;18(8):637–644.

16. Kjoller E, Kober L, Iversen K, Torp-Pedersen C; Trace Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. *Eur J Heart Fail.* 2004;6(1):71–77.

17. Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. *Eur J Heart Fail.* 2007;9(9):942–948.

18. Boomsma-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. *Diabetologia.* 2012;55(8):2154–2162.

19. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl.* 1993;16:5–40.

20. Boschetto P, Fucili A, Stendardo M, et al. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. *Respir Res.* 2012;13(11):13.

21. Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. *Eur J Heart Fail.* 2007;9(9):942–948.

22. Guder G, Brenner S, Stork S, Hoes A, Rutten FH. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. *Eur J Heart Fail.* 2014;16(12):1273–1282.
### Supplementary material

**Table S1** Characteristics of the 236 patients with established heart failure who were invited for spirometry, divided into participants and nonparticipants

|                          | Participants (n=121) | Nonparticipants (n=115) | P-value |
|--------------------------|----------------------|-------------------------|---------|
| Male sex                 | 46.3                 | 55.7                    | 0.15    |
| Mean age in years (SD)   | 77.0 (11.4)          | 76.6 (11.9)             | 0.91    |
| Hypertension             | 56.7                 | 53.0                    | 0.63    |
| Diabetes mellitus        | 30.6                 | 26.1                    | 0.44    |
| Prior myocardial infarction | 33.1              | 32.2                    | 0.89    |
| Angina pectoris          | 22.3                 | 13.0                    | 0.06    |
| Atrial fibrillation      | 54.5                 | 50.4                    | 0.53    |
| eGFR <60 mL/m²           | 38.8                 | 37.4                    | 0.82    |
| Medication               |                      |                         |         |
| Diuretics                | 84.3                 | 73.0                    | 0.03    |
| ACE-i                    | 54.5                 | 52.2                    | 0.72    |
| β-blocker                | 59.9                 | 52.2                    | 0.29    |
| Digoxin                  | 24.0                 | 21.7                    | 0.68    |

**Note:** Numbers are cases (%) unless specified otherwise.

**Abbreviations:** SD, standard deviation; eGFR, estimated glomerular filtration rate according to the modification of diet in renal diseases formula; ACE-i, angiotensin converting enzyme inhibitor.